menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Deliver reliable, scalable, and regulatory-ready eCOA for global Central Nervous System (CNS) trials.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Expert guidance for capturing high-quality, regulatory compliant data from the right participants, at the right time, in clinic or at home.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Improve your data quality, monitor for proper technique and leverage the power of AI to make interpretation of spirometry tests easier, faster and more consistent.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
    • Contact
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Neuroscience
        • eCOA Rapid Start
        • eCOA Science Services
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
        • eCOA Live
        • eCOA Multimedia
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Respiratory Solutions for Healthcare Providers
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
    • Contact
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Get started
    • Log in
    • Get started
  1. Home About Newsroom Clario Teams with WeWork to Enhance Hybrid Work Strategy

Clario Teams with WeWork to Enhance Hybrid Work Strategy

Flexible Workspace to be Accessible for Thousands of Employees Worldwide

Collaboration with WeWork to support a more distributed, inclusive workforce

PHILADELPHIA, PA and NEW YORK, NY February 22, 2023 – Clario, a leading healthcare research and technology company that generates the richest clinical evidence for pharmaceutical, biotech and medical device partners, and WeWork (NYSE: WE), a leading flexible space provider, have partnered to provide Clario’s workforce with WeWork All Access passes and flexible space across the United States, United Kingdom, Germany, Belgium, Hungary, and Costa Rica, giving colleagues even more flexibility with where they work.

COVID changed how and where Clario’s colleagues wanted to engage with each other, and it became clear that Clario needed to balance different needs for different people. Engaging with WeWork, Clario designed a solution that offers a balance between fixed, flexible and remote working.

Combining two WeWork solutions – All Access and private space – Clario’s people will now have access to inspiring workspaces designed for heads-down work or collaborative meetings. Clario’s space will include common areas and shared spaces within the building, including lounge spaces, reading nooks, phone booths for private calls, conference rooms and more. Hybrid working gives individuals and teams at Clario the ability to shape their own work schedules based on their location, workflow and what suits them best on a particular day.

WeWork provides a one-stop solution for enterprise companies looking to adapt their real estate portfolio and update their workplace strategy to meet the dynamic needs of today. WeWork’s streamlined global space-as-a-solution platform reduces the complexity of leasing real estate, allowing companies to focus on what matters most: providing employees with the flexibility to enjoy an exceptional workplace experience on their schedule.

“Our work with Clario is indicative of the demand for flexibility that companies look for when planning the future of their business. Clario is leading the way in embracing a forward-thinking workplace strategy defined by flexibility and collaboration that complements their plans for innovation alongside their talent attraction and retention needs. We are excited to welcome Clario to the WeWork community globally with a workspace that is primed for collaboration and connection as they look to support employees with a new way of working,” said Melinda Holland, COO, Americas at WeWork.

“At Clario we believe our people are our most material differentiator. They define who we are and how we compete in the marketplace. Part of attracting and ultimately retaining talent like ours is to ensure we listen to what people value most. We have learned from countless surveys and feedback sessions that people want flexibility. They want time back, to better balance their personal and professional lives. How work is done has been changed by ever advancing technology and where work needs to be done has forever changed. Working with WeWork has allowed us flexibility to chose locations that fit our employee base. It has reduced travel time, improved work efficiency and allowed our employees and Clario as a company greater overall flexibility. This partnership is one that we are truly excited about and look forward to the future,” said David E. Fusco, EVP, Chief Human Capital Officer at Clario.


About Clario

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allow our partners to transform lives. Clario’s Trial Anywhere™ solutions have been powering hybrid and decentralized clinical trials (DCT) for over 20 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years. 

For more information, go to Clario.com or follow us on LinkedIn and Twitter.

About WeWork

WeWork (NYSE: WE) was founded in 2010 with the vision to create environments where people and companies come together and do their best work. Since then, we’ve become one of the leading global flexible space providers committed to delivering technology-driven turnkey solutions, flexible spaces, and community experiences. For more information about WeWork, please visit us at wework.com.

Examples:

  • Boston Consulting Group: Boston Consulting Group Opens First-Ever Office in Nashville at WeWork
  • Revolut: Revolut becomes WeWork’s first enterprise member to sign new space using cryptocurrency
  • Goldman Sachs: Goldman Sachs to take space with WeWork in Birmingham
Back to newsroom
Share
Twitter Facebook LinkedIn

Related News

See all news

Biological Psychiatry Study Shows Speech-Latency Vocal Biomarker Can Strengthen Drug–Placebo Separation in Schizophrenia Trials 

February 26, 2026 Read more

Clario leads the way in responsible artificial intelligence with ISO 42001 certification, audited by Schellman

February 18, 2026 Read more

Thermo Fisher Scientific to Acquire Clario, Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights

October 29, 2025 Read more
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Get started

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.

Step 1 of 2 - Quick and easy to complete

Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2026 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum